Company intelligence / Profile preview
Navrogen
Cheyney, Pennsylvania, United Statesnavrogen.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
Navrogen has developed a proprietary platform focused on overcoming tumor-induced suppression of the humoral immune response. The company’s lead programs target novel HIO factors with antibody-based therapies, including ADCs. As of May 2025, its pipeline remains in preclinical or IND-enabling stages; no clinical trial results have been published yet. Recent financing rounds support advancement toward first-in-human studies.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Diagnostic assaysImmuno-oncology agents
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Navrogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Navrogen.